Enter your email address to receive updates
Search By Trade Name
Trade name | Generic name | Classification
A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z 
Generic Name
Diatrizoate and Iodipamide (Local)
Trade Name
Risk Category
  • Positive evidence of human fetal risk exists.
  • Potential benefits may warrant use of the drug in pregnant women despite potential risks (e.g. life threatening situations or serious illness).
  • Studies in animals and/or humans have demonstrated fetal abnormalities.
  • Fetal risk involved in use of drug, clearly outweighs potential benefit.
  • Contraindicated in women who are or may become pregnant. Don’t use.
FDA Pregnancy Risk Categories

Place (not click) your mouse cursor over the bold words in the text below to receive description

  • A local radio-opaque diagnostic aid used in hysterosalpingography.
  • Fetal Risk
    Fetal Risk
  • Elective radiographic assessment of genital tract during pregnancy is not indicated.
  • Breast Feeding
    Breast Feeding
  • Diatrizoate meglumine and iodipamide meglumine administered intravascularly has been found to be excreted in breast milk.
  • Because small amounts of these agents may be absorbed following intrauterine instillation, caution should be exercised when any diagnostic intrauterine radiopaque agent is administered to a nursing woman.
  • Breast feeding isn’t recommended for at least 24 hours after its use.
  • Other Trade Names
    The information on this Web site is not intended as a substitute for the advice and care of your doctor or other health-care provider. Always consult your doctor if you have any questions about exposures during pregnancy and lactation, and before you take any medications. Please read the Terms and Conditions before using this website.
      Tell A Friend

        Your Friend
     5   +   8    =  
      Calculate Birth Date
    Enter the first day of the last menstruation
    Month Day Year
    Month Day Year